Book an appointment with us, or search the directory to find the right lawyer for you directly through the app.
Find out moreIn May Law Update’s edition, we examined the continued relevance of English law across MENA jurisdictions and why it remains a cornerstone of commercial transactions, dispute resolution, and cross-border deal structuring.
From the Dubai Court’s recognition of Without Prejudice communications to anti-sandbagging clauses, ESG, joint ventures, and the classification of warranties, our contributors explore how English legal concepts are being applied, interpreted, and adapted in a regional context.
With expert insight across sectors, including capital markets, corporate acquisitions, and estate planning, this issue underscores that familiarity with English law is no longer optional for businesses in MENA. It is essential.
2025 is set to be a game-changer for the MENA region, with legal and regulatory shifts from 2024 continuing to reshape its economic landscape. Saudi Arabia, the UAE, Egypt, Iraq, Qatar, and Bahrain are all implementing groundbreaking reforms in sustainable financing, investment laws, labor regulations, and dispute resolution. As the region positions itself for deeper global integration, businesses must adapt to a rapidly evolving legal environment.
Our Eyes on 2025 publication provides essential insights and practical guidance on the key legal updates shaping the year ahead—equipping you with the knowledge to stay ahead in this dynamic market.
The UAE has introduced Federal Law No. 38 of 2024, replacing Federal Law No. 8 of 2019 concerning medical products, pharmacists, and pharmaceutical establishments. The new legislation came into force on the 2nd of January, 2025 and implements significant reforms to the regulation of medical products and pharmaceutical practices, with a focus on enhanced safety, stricter compliance, and modernised regulatory frameworks.
Key Provisions:
Implications for Stakeholders:
Comparative Analysis: Federal Law No. 8 of 2019 vs. Federal Law No. 38 of 2024 | ||||||||||||||||||||||||||||||||
|
Conclusion:
Federal Law No. 38 of 2024 introduces a modernised regulatory landscape for the UAE’s pharmaceutical sector, enhancing consumer protection, regulatory efficiency, and innovation incentives. Stakeholders should review internal compliance policies to align with the new provisions and engage proactively with the EDE to ensure continued market access and regulatory adherence.
For further information or specific legal guidance, please feel free to contact our healthcare practice group team members Andrea Tithecott (A.Tithecott@tamimi.com) or Christina Sochacki (C.Sochacki@tamimi.com)
To learn more about our services and get the latest legal insights from across the Middle East and North Africa region, click on the link below.